Table 2 Performances of two immunohistochemistry methods against in situ hybridization as the 'gold standard' for detection of ERBB2 gene amplification
From: Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Collection | Test | Test positive if | Reference test | Number of patients | Test performances | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
True positive | True negative | False positive | False negative | Total | Accuracy | Sensitivity | Specificity | Positive predictive value | Negative predictive value | ||||
Archival CPP | HercepTest | 2+ 3+ ≥10% | SISH | 13 | 14 | 2 | 1 | 30 | 90.0% | 92.9% | 87.5% | 86.7% | 93.3% |
Archival CPP | Ventana 4B5 | 2+ 3+ ≥10% | SISH | 14 | 7 | 9 | 0 | 30 | 70.0% | 100.0% | 43.8% | 60.9% | 100.0% |
Archival CPP | HercepTest | 2+ 3+ ≥50% | SISH | 10 | 16 | 0 | 4 | 30 | 86.7% | 71.4% | 100.0% | 100.0% | 80.0% |
Archival CPP | Ventana 4B5 | 2+ 3+ ≥50% | SISH | 13 | 16 | 1 | 0 | 30 | 96.7% | 100.0% | 94.1% | 92.9% | 100.0% |
